Sanara Medtech, Inc. (SMTI)

NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-10-23

$32.80-0.24%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Sanara Medtech, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	31.1M
EPS	—	0.137
Annual ending 2026-12-31
Revenue	—	116.83M
EPS	—	0.19
Annual ending 2027-12-31
Revenue	—	131.6M
EPS	—	0.585

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Gross profit grows to support margin improvement	Gross profit improved by $4.3M, reflecting pricing and efficiency gains.	Intact	Gross profit falls below $22M in next 4 quarters	Gross profit: $26.155M FY2026-Q2; GAAP. Published target: Gross profit >= $25.9M next 4 quarters. Target period is not explicitly aligned with this observation. Source published Aug 11, 202626,155,410 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 4b90a0e1-3223-473f-b6ba-b668ecafc4cd. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 2 of last 2 quarters. Gross margin improved from 92% in 2025-Q2 to 93% in 2026-Q2 and similarly in Q1. Gross profit increased by $2.3 million year-over-year in Q2 2026. Management's focus on product mix and revenue growth is reflected in stable to improving gross margins, indicating delivery on this priority. Delivery assessment Oct 24, 2026
Operating income increases to sustain positive trajectory	Operating income rose from $0.8M to $2.6M, showing better cost control.	Intact	Operating income falls below $1.5M in next 4 quarters	Operating income: $1.78M FY2026-Q2; GAAP. Published target: Operating income >= $2.6M next 4 quarters. Target period is not explicitly aligned with this observation. Source published Aug 11, 20261,780,377 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 4b90a0e1-3223-473f-b6ba-b668ecafc4cd. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 2 of last 2 quarters. Operating income declined from $2.5 million in 2025-Q2 to $1.8 million in 2026-Q2 but improved year-to-date from $3.3 million to $4.4 million. Management acknowledges higher SG&A expenses but operating income trajectory year-to-date is improving, showing partial delivery on this priority. Delivery assessment Oct 24, 2026
Increase revenue to about $118.5M in FY26	A primary condition in Sanara Medtech, Inc.'s published investment case. The stated target is ~$118.5M.	Intact	Revenue falls below $110M in FY26	Revenue: $28.137M FY2026-Q2; GAAP. Published target: ~$118.5M. Target period is not explicitly aligned with this observation. Source published Aug 11, 202628,136,757 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 4b90a0e1-3223-473f-b6ba-b668ecafc4cd. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 2 of last 2 quarters. Net revenue grew from $25.8 million in 2025-Q2 to $28.1 million in 2026-Q2 (+9% YoY) and increased 14% year-to-date to $55.9 million. Management has consistently emphasized revenue growth driven by soft tissue repair products and expanding market penetration, and the financials show delivering growth aligned with this priority. Delivery assessment Oct 24, 2026

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS: comparable history unavailable.

FY2027 revenue: comparable history unavailable.

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	Unavailable	Unavailable	1 / 2
2026-07-25	Unavailable	Unavailable	1 / 2
2026-07-26	Unavailable	Unavailable	1 / 2
2026-07-27	Unavailable	Unavailable	1 / 2
2026-07-28	Unavailable	Unavailable	1 / 2
2026-07-29	Unavailable	Unavailable	1 / 2
2026-07-30	Unavailable	Unavailable	1 / 2
2026-07-31	Unavailable	Unavailable	1 / 2
2026-08-01	Unavailable	Unavailable	1 / 2
2026-08-02	Unavailable	Unavailable	1 / 2
2026-08-03	Unavailable	Unavailable	1 / 2
2026-08-04	Unavailable	Unavailable	1 / 2
2026-08-05	Unavailable	Unavailable	1 / 2
2026-08-06	Unavailable	Unavailable	1 / 2
2026-08-08	Unavailable	Unavailable	1 / 2
2026-08-09	Unavailable	Unavailable	1 / 2
2026-08-10	Unavailable	Unavailable	1 / 2
2026-08-12	Unavailable	Unavailable	1 / 2
2026-08-13	Unavailable	Unavailable	1 / 2
2026-08-14	Unavailable	Unavailable	1 / 2
2026-08-15	Unavailable	Unavailable	1 / 2
2026-08-16	Unavailable	Unavailable	1 / 2
2026-08-17	Unavailable	Unavailable	1 / 2
2026-08-18	Unavailable	Unavailable	1 / 2
2026-08-19	Unavailable	Unavailable	1 / 2
2026-08-20	Unavailable	Unavailable	1 / 2
2026-08-21	Unavailable	Unavailable	1 / 2
2026-08-22	Unavailable	Unavailable	1 / 2
2026-08-23	Unavailable	Unavailable	1 / 2
2026-08-24	Unavailable	Unavailable	1 / 2
2026-08-25	Unavailable	Unavailable	1 / 2
2026-08-26	Unavailable	Unavailable	1 / 2
2026-08-27	Unavailable	Unavailable	1 / 2
2026-08-28	Unavailable	Unavailable	1 / 2
2026-08-29	Unavailable	Unavailable	1 / 2
2026-08-30	Unavailable	Unavailable	1 / 2
2026-08-31	Unavailable	Unavailable	1 / 2
2026-09-01	Unavailable	Unavailable	1 / 2
2026-09-02	Unavailable	Unavailable	1 / 2
2026-09-03	Unavailable	Unavailable	1 / 2
2026-09-04	Unavailable	Unavailable	1 / 2
2026-09-05	Unavailable	Unavailable	1 / 2
2026-09-06	Unavailable	Unavailable	1 / 2
2026-09-07	Unavailable	Unavailable	1 / 2
2026-09-08	Unavailable	Unavailable	1 / 2
2026-09-09	Unavailable	Unavailable	1 / 2
2026-09-10	Unavailable	Unavailable	1 / 2
2026-09-11	Unavailable	Unavailable	1 / 2
2026-09-12	Unavailable	Unavailable	1 / 2
2026-09-13	Unavailable	Unavailable	1 / 2
2026-09-14	Unavailable	Unavailable	1 / 2
2026-09-15	Unavailable	Unavailable	1 / 2
2026-09-16	Unavailable	Unavailable	1 / 2
2026-09-17	Unavailable	Unavailable	1 / 2
2026-09-18	Unavailable	Unavailable	1 / 2
2026-09-19	Unavailable	Unavailable	1 / 2
2026-09-20	Unavailable	Unavailable	1 / 2
2026-09-21	Unavailable	Unavailable	1 / 2
2026-09-22	Unavailable	Unavailable	1 / 2
2026-09-23	Unavailable	Unavailable	1 / 2
2026-09-24	Unavailable	Unavailable	1 / 2
2026-09-25	Unavailable	Unavailable	1 / 2
2026-09-26	Unavailable	Unavailable	1 / 2
2026-09-27	Unavailable	Unavailable	1 / 2
2026-09-28	Unavailable	Unavailable	1 / 2
2026-09-29	Unavailable	Unavailable	1 / 2
2026-09-30	Unavailable	Unavailable	1 / 2
2026-10-01	Unavailable	Unavailable	1 / 2
2026-10-02	Unavailable	Unavailable	1 / 2
2026-10-03	Unavailable	Unavailable	1 / 2
2026-10-04	Unavailable	Unavailable	1 / 2
2026-10-05	Unavailable	Unavailable	1 / 2
2026-10-06	Unavailable	Unavailable	1 / 2
2026-10-07	Unavailable	Unavailable	1 / 2
2026-10-08	Unavailable	Unavailable	1 / 2
2026-10-09	Unavailable	Unavailable	1 / 2
2026-10-10	Unavailable	Unavailable	1 / 2
2026-10-11	Unavailable	Unavailable	1 / 2
2026-10-12	Unavailable	Unavailable	1 / 2
2026-10-13	Unavailable	Unavailable	1 / 2
2026-10-14	Unavailable	Unavailable	1 / 2
2026-10-15	Unavailable	Unavailable	1 / 2
2026-10-16	Unavailable	Unavailable	1 / 2
2026-10-17	Unavailable	Unavailable	1 / 2
2026-10-18	Unavailable	Unavailable	1 / 2
2026-10-19	Unavailable	Unavailable	1 / 2
2026-10-20	Unavailable	Unavailable	1 / 2
2026-10-21	Unavailable	Unavailable	1 / 2
2026-10-22	Unavailable	Unavailable	1 / 2
2026-10-23	Unavailable	Unavailable	1 / 2
2026-10-24	Unavailable	Unavailable	1 / 2

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	2	0
2026-06-01	3	0
2026-07-01	3	2
2026-08-01	1	3
2026-09-01	1	3
2026-10-01	0	3

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 0 Buy / Strong Buy · 3 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Gross profit grows to support margin improvementGross profit: $26.155M
Operating income increases to sustain positive trajectoryOperating income: $1.78M
Increase revenue to about $118.5M in FY26Revenue: $28.137M

Next proof point

Nov 11, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

0.3%Typical daily move · historical

Downside history

-47.4%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Sanara Medtech, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a growth-oriented healthcare business with strong recent financial performance, not yet a proven durable compounder because earnings quality is fragile and the company is loss-making on the value dimension. The long-term thesis is intact, though the signal has shifted from mildly favorable to mixed.

What's priced into Sanara Medtech, Inc.

The valuation evidence describes SMTI as cheap versus peers, with a justified priced-in assessment and low fragility. The expectations gap is slightly negative, but the evidence does not show that the market assumes strong execution.

What the fundamentals likely do

Near term, revenue growth and gross margins are progressing: second-quarter revenue rose 9% year over year, and gross margin improved to 93%. Operating income fell year over year in the quarter but improved year to date, while repeated earnings misses and a 61% estimated chance of a next-quarter miss point to elevated execution risk; a recent litigation filing adds uncertainty.

What Sanara Medtech, Inc. hinges on

The multi-year view depends on continued growth in soft tissue repair products and market penetration, alongside better operating income as management addresses higher selling, general, and administrative expenses. Near-term outcomes hinge on whether guidance is maintained, whether weakening jobs data raises recession concerns, and whether healthcare bellwethers continue to report strong results and guidance.